The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia
Ayşegül Erdem, Silvia Marín, Diego A. Pereira‐Martins, R. Cortès, Alan Cunningham, Maurien Pruis, Bauke de Boer, Fiona A.J. van den Heuvel, Marjan Geugien, Albertus T.J. Wierenga, Annet Z. Brouwers-Vos, Eduardo Magalhães Rego, Gerwin Huls, Marta Cascante, Jan Jacob Schuringa
Abstract
Abstract Acute myeloid leukemia remains difficult to treat due to strong genetic heterogeneity between and within individual patients. Here, we show that Pyruvate dehydrogenase kinase 1 (PDK1) acts as a targetable determinant of different metabolic states in acute myeloid leukemia (AML). PDK1 low AMLs are OXPHOS-driven, are enriched for leukemic granulocyte-monocyte progenitor (L-GMP) signatures, and are associated with FLT3 -ITD and NPM1 cyt mutations. PDK1 high AMLs however are OXPHOS low , wild type for FLT3 and NPM1 , and are enriched for stemness signatures. Metabolic states can even differ between genetically distinct subclones within individual patients. Loss of PDK1 activity releases glycolytic cells into an OXPHOS state associated with increased ROS levels resulting in enhanced apoptosis in leukemic but not in healthy stem/progenitor cells. This coincides with an enhanced dependency on glutamine uptake and reduced proliferation in vitro and in vivo in humanized xenograft mouse models. We show that human leukemias display distinct metabolic states and adaptation mechanisms that can serve as targets for treatment.